ZnT8 has been considered as an appealing target for preserving beta cell function in T2D because its loss of function mutations, including a pArg138* truncating variant, are associated with a more than 50% lower risk of developing T2D [4,5]. This evidence concerns the gene SLC30A8 and type 2 diabetes mellitus.